What Zhaoke Ophthalmology is
•	Zhaoke Ophthalmology was founded in 2017 and is listed on the Hong Kong Stock Exchange
(SEHK: 6622).
•	It is described as a “fully integrated ophthalmic platform — From laboratory to market.”

•	The company focuses on research & development, manufacturing, and commercialisation of therapies for eye diseases (both front- and back-of-the-eye).


Key focus areas & capabilities
•	Drug portfolio: Zhaoke has both innovative (novel) and generic ophthalmic drugs.

•	Therapeutic indications: They focus on six major eye diseases, including dry eye disease
(DED), myopia, presbyopia, wet age-related macular degeneration (wAMD), diabetic macular
edema (DM E) and glaucoma.
•	Manufacturing & infrastructure: They have a commercial-scale advanced manufacturing facility in Nansha New District, Guangzhou, built for ophthalmic drug production and compliant with multiple regulatory regimes (China, US, EU).
•	R&D and regulatory: They are developing drug candidates through pre-clinical, clinical and registration phases. They also license in/out assets and form partnerships.


Business strategy & ambitions
•	Zhaoke's ambition is to become a global leader in ophthalmology, leveraging its integrated platform from R&D through manufacturing and commercialization.
•	They actively form licensing and partnership agreements with international companies to access additional assets or markets. For example:
•	Licensing from Visus Therapeutics, Inc. for two presbyopia drugs (BRIMOCHOL PF & Carbachol PF) for Greater China, South Korea and Southeast Asia.
•	Licensing from Panoptica, Inc. for a topical treatment for neovascular eye diseases (PAN- 90806) in China, South Korea and Southeast Asia.
•	Partnership with FAREVA (a French CMO) to strengthen manufacturing presence and
g lobal standard s.
•	They emphasise “from laboratory to market” meaning they own or manage much of the value-
chain in-house (R&D, manufacturing, sales) which gives them strategic control.
•	They are expanding commercial team and capabilities, plus focusing on regulatory, production
scale-up and market launch readiness,


Milestones & Highlights

•	Two of their products passed on-site inspection for drug registration and GMP compliance by
China's regulatory authorities.
•	Their manufacturing facility occupies about 7,600 sqm in Nansha New DistriCt.
•	They enrolled the first patient in a Phase III clinical trial for their CsA (Cyclosporine) Ophthalmic
Gel for dry eye disease.
•	The licensing agreement with Visus includes significant upfront and milestone payments: e.g.,
$15 million upfront and up to $115 million in milestones.


Summary — What the company is about
In simple terms: Zhaoke Ophthalmology is a Chinese ophthalmic pharmaceutical company that builds and operates an integrated platform for eye-care therapies (both generic and novel), from early research to manufacturing and commercialisation. They specialise in major ocular diseases, have in-house manufacturing at scale, and partner internationally to broaden their pipeline and market reach. Their goal is to lead in eye-care globally.
